Publication: Dalbavancin for the Treatment of Prosthetic Joint Infections: A Narrative Review
Loading...
Official URL
Full text at PDC
Publication Date
2021-05-31
Advisors (or tutors)
Editors
Journal Title
Journal ISSN
Volume Title
Publisher
MPDI
Citations
Exportar
Abstract
Dalbavancin (DAL) is a lipoglycopeptide with bactericidal activity against a very wide range of Gram-positive microorganisms. It also has unique pharmacokinetic properties, namely a prolonged half-life (around 181 h), which allows a convenient weekly dosing regimen, and good diffusion in bone tissue. These features have led to off-label use of dalbavancin in the setting of bone and joint infection, including prosthetic joint infections (PJI). In this narrative review, we go over the pharmacokinetic and pharmacodynamic characteristics of DAL, along with published in vitro and in vivo experimental models evaluating its activity against biofilm-embedded bacteria. We also examine published experience of osteoarticular infection with special attention to DAL and PJI.